New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
News|Articles|March 1, 2024
Presenting Our March Theme: Mood Disorders
Author(s)Erin O'Brien
Write to us now to be part of our series focused on mood disorders this month.
Advertisement
This year, Psychiatric Times® is introducing monthly themes that speak to various aspects of psychiatry and issues relevant to psychiatric clinicians. Our March theme is Mood Disorders, which will include expert discussions on identifying, treating, and managing mood disorders such as major depressive disorder and bipolar disorder.
How do you address mood disorders in your patients? Let us know! Write to us now at
Advertisement
Related to this article
Phase 1 driving simulation finds bedtime GlyphAllo for major depressive disorder shows no next-morning driving impairment, while advancing allopregnanolone-based oral treatment development.
Helus Pharma advances oral deuterated psilocin HLP003 for MDD, detailing new efficacy and safety analyses plus ongoing phase 3 PARADIGM trial updates.
Caplyta phase 3 data show rapid, significant mania symptom relief in bipolar I by day 3, sustained to week 3, with tolerable adverse effects.
How tuning body signals with closed-loop sound and chill tech may ease dissociation and anhedonia, offering drug-free add-ons to therapy.
Phase 2 MOONLIGHT-1 shows JNJ-5120/PIPE-307 misses day‑5 MADRS improvement in MDD, yet remains well tolerated as J&J reviews next steps.
Experts dissect 10 common antidepressant myths, separating evidence from fear on efficacy, addiction, suicide risk, withdrawal, and safe tapering.
Health Canada has authorized a 200-participant phase 2 trial testing a single psilocybin dose for major depressive disorder, with dosing set to begin in 2027.
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Grants Breakthrough Device Designation to NET Recovery's Device for Stimulant Use Disorder
2
Treating PTSD Among Veterans at Risk for Suicide
3
Using Psychotherapy for the Prevention of Relapse in Schizophrenia
4
Positive Phase 2 Topline Results: Remlifanserin for the Treatment of Alzheimer Disease Psychosis
5